Annual Reports

Immunovaccine

Date	Form	Description	PDF	XBRL	Pages
03/30/20	40-F	Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4 Documents EX-99.1 EX-99.2 EX-99.3 EX-99.4 EX-99.5 EX-99.6 EX-99.7 EX-99.8			180
04/01/19	40-F	Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4 Documents EX-99.1 EX-99.2 EX-99.3 EX-99.4 EX-99.5 EX-99.6 EX-99.7 EX-99.8			172

IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV's proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.

Clinical Trials

Ongoing Trials

● Expanded Access

● Investigator-initiated Trials

DPX-Survivac

Research & Development

● Infectious Diseases

Intellectual Property